Compile Data Set for Download or QSAR
Report error Found 62 of ph data with Target = 'cGMP-dependent 3',5'-cyclic phosphodiesterase'
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 50166893BDBM50166893(2-(3,4-Dimethoxy-benzyl)-7-[(R)-1-((R)-1-hydroxy-e...)
Affinity DataIC50: 1nMpH: 7.2 T: 2°CAssay Description:Assay: PDE2A is assayed with FL-cAMP as substrate. An enzyme titration is first performed to determine the working concentration of PDE. The concentr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2019
Entry Details
US Patent
PDB3D3D Structure (crystal)
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 50444038BDBM50444038(CHEMBL3092563 | US9669035, B-5)
Affinity DataIC50: 1.40nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 50425123BDBM50425123(CHEMBL2313234 | US9669035, B-3)
Affinity DataIC50: 2.30nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 50026827BDBM50026827(US9669035, B-6 | CHEMBL3331516)
Affinity DataIC50: 4.80nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 292716BDBM292716(US10105349, Example 22 | 1-(2-Chloro-5-(cyclobutyl...)
Affinity DataIC50: 5.90nMpH: 7.2 T: 2°CAssay Description:Assay: PDE2A is assayed with FL-cAMP as substrate. An enzyme titration is first performed to determine the working concentration of PDE. The concentr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2019
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 50026829BDBM50026829(US9669035, B-7 | CHEMBL3331514)
Affinity DataIC50: 6.20nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 50026828BDBM50026828(US9669035, B-8 | CHEMBL3331515)
Affinity DataIC50: 6.5nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 50026821BDBM50026821(US9669035, B-1b | CHEMBL3331521 | US11419874, Exam...)
Affinity DataIC50: 7.40nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 50026826BDBM50026826(US9669035, B-2 | CHEMBL3331517 | US11419874, Examp...)
Affinity DataIC50: 7.80nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 292715BDBM292715(US10105349, Example 21 | 1-(5-Butoxy-2-chloropheny...)
Affinity DataIC50: 9.40nMpH: 7.2 T: 2°CAssay Description:Assay: PDE2A is assayed with FL-cAMP as substrate. An enzyme titration is first performed to determine the working concentration of PDE. The concentr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2019
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 179970BDBM179970(US9669035, B-9)
Affinity DataIC50: 9.5nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 50026820BDBM50026820(US9669035, B-10 | CHEMBL3331513)
Affinity DataIC50: 10nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 179972BDBM179972(US9669035, B-11)
Affinity DataIC50: 11nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 50026825BDBM50026825(US9669035, B-12 | CHEMBL3331518)
Affinity DataIC50: 12nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 292713BDBM292713(US10105349, Example 20 | 1-(5-Butoxy-2-chloropheny...)
Affinity DataIC50: 12nMpH: 7.2 T: 2°CAssay Description:Assay: PDE2A is assayed with FL-cAMP as substrate. An enzyme titration is first performed to determine the working concentration of PDE. The concentr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2019
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 50026821BDBM50026821(US9669035, B-1b | CHEMBL3331521 | US11419874, Exam...)
Affinity DataIC50: 13nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 181755BDBM181755(US9669035, B-25)
Affinity DataIC50: 18nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 50425124BDBM50425124(CHEMBL2313233 | US9669035, B-13)
Affinity DataIC50: 20nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 50425125BDBM50425125(CHEMBL2313232 | US9669035, B-4)
Affinity DataIC50: 20nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 179977BDBM179977(US9669035, B-14)
Affinity DataIC50: 21nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 179978BDBM179978(US9669035, B-15)
Affinity DataIC50: 22nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 181763BDBM181763(US9669035, B-26)
Affinity DataIC50: 22nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 292714BDBM292714(US10105349, Example 17 | 1-(5-Butoxy-2-chloropheny...)
Affinity DataIC50: 28nMpH: 7.2 T: 2°CAssay Description:Assay: PDE2A is assayed with FL-cAMP as substrate. An enzyme titration is first performed to determine the working concentration of PDE. The concentr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2019
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 50026824BDBM50026824(US9669035, B-16 | CHEMBL3331519)
Affinity DataIC50: 30nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 179980BDBM179980(US9669035, B-17)
Affinity DataIC50: 35nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 179981BDBM179981(US9669035, B-18)
Affinity DataIC50: 36nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 181676BDBM181676(US9669035, B-22a)
Affinity DataIC50: 44nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 179983BDBM179983(US9669035, B-20)
Affinity DataIC50: 45nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 179982BDBM179982(US9669035, B-19)
Affinity DataIC50: 46nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 181673BDBM181673(US9669035, B-21)
Affinity DataIC50: 49nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 181678BDBM181678(US9669035, B-23)
Affinity DataIC50: 52nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 162879BDBM162879(US9056863, Example Ic1 | US11419874, Example 28)
Affinity DataIC50: 69nMpH: 7.6 T: 2°CAssay Description:A typical PDE2A assay was performed as follows: the assay was performed in 60 μL samples containing a fixed amount of the PDE2A enzyme (sufficie...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 292712BDBM292712(US10105349, Example 19 | 8-Chloro-1-(2,5-dichlorop...)
Affinity DataIC50: 73nMpH: 7.2 T: 2°CAssay Description:Assay: PDE2A is assayed with FL-cAMP as substrate. An enzyme titration is first performed to determine the working concentration of PDE. The concentr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2019
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 182096BDBM182096(US9669035, B-27)
Affinity DataIC50: 74nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 182226BDBM182226(US9669035, B-28)
Affinity DataIC50: 91nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 182234BDBM182234(US9669035, B-29)
Affinity DataIC50: 120nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 182294BDBM182294(US9669035, B-30)
Affinity DataIC50: 130nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 181713BDBM181713(US9669035, B-24)
Affinity DataIC50: 190nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 182857BDBM182857(US9669035, B-31)
Affinity DataIC50: 330nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 182858BDBM182858(US9669035, B-32)
Affinity DataIC50: 350nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 162878BDBM162878(US9056863, Example Ib1)
Affinity DataIC50: 471nMpH: 7.6 T: 2°CAssay Description:A typical PDE2A assay was performed as follows: the assay was performed in 60 μL samples containing a fixed amount of the PDE2A enzyme (sufficie...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 162877BDBM162877(US9056863, Example Ia2)
Affinity DataIC50: 504nMpH: 7.6 T: 2°CAssay Description:A typical PDE2A assay was performed as follows: the assay was performed in 60 μL samples containing a fixed amount of the PDE2A enzyme (sufficie...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 22926BDBM22926(3-(6-amino-9H-purin-9-yl)nonan-2-ol | Erythro-9-(2...)
Affinity DataIC50: 800nMpH: 7.5 T: 2°CAssay Description:Enzymatic activities were assayed using [3H] cAMP and [3H]cGMP as substrate.More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/8/2012
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 119850BDBM119850(US8691986, 17 | US9718803, 5.19)
Affinity DataIC50: 2.16E+3nMpH: 7.2 T: 2°CAssay Description:IMAP TR-FRET progressive binding system, FAM-cAMP substrate were from Molecular Devices (Sunnyvale, Calif.). The PDE IMAP assay was conducted in a 3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/30/2014
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 119849BDBM119849(US8691986, 16 | US9718803, 30.4)
Affinity DataIC50: 3.30E+3nMpH: 7.2 T: 2°CAssay Description:IMAP TR-FRET progressive binding system, FAM-cAMP substrate were from Molecular Devices (Sunnyvale, Calif.). The PDE IMAP assay was conducted in a 3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/30/2014
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 123687BDBM123687(US8741907, 3 | US9067945, 2)
Affinity DataIC50: 4.00E+3nMpH: 7.5Assay Description:The test substances are dissolved in 100% DMSO and serially diluted to determine their in vitro effect on PDE 9A. 2 uL portions of the diluted substa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/5/2014
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 123687BDBM123687(US8741907, 3 | US9067945, 2)
Affinity DataIC50: 4.00E+3nMpH: 7.5Assay Description:The test substances are dissolved in 100% DMSO and serially diluted to determine their in vitro effect on PDE 9A. Typically, serial dilutions from 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2016
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 119844BDBM119844(US8691986, 10)
Affinity DataIC50: 7.38E+3nMpH: 7.2 T: 2°CAssay Description:IMAP TR-FRET progressive binding system, FAM-cAMP substrate were from Molecular Devices (Sunnyvale, Calif.). The PDE IMAP assay was conducted in a 3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/30/2014
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 119837BDBM119837(US8691986, 3)
Affinity DataIC50: 1.00E+4nMpH: 7.2 T: 2°CAssay Description:IMAP TR-FRET progressive binding system, FAM-cAMP substrate were from Molecular Devices (Sunnyvale, Calif.). The PDE IMAP assay was conducted in a 3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/30/2014
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Intra-Cellular Therapies

US Patent
LigandChemical structure of BindingDB Monomer ID 119836BDBM119836(US8691986, 2)
Affinity DataIC50: 1.00E+4nMpH: 7.2 T: 2°CAssay Description:IMAP TR-FRET progressive binding system, FAM-cAMP substrate were from Molecular Devices (Sunnyvale, Calif.). The PDE IMAP assay was conducted in a 3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/30/2014
Entry Details
US Patent

Displayed 1 to 50 (of 62 total ) | Next | Last >>
Jump to: